Aptevo Therapeutics
APVO
1 hedge funds and large institutions have $107M invested in Aptevo Therapeutics in 2020 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
2,034% more capital invested
Capital invested by funds: $5M → $107M (+$102M)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$48.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$412K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$308K |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$210K |
| 4 |
WG
Winton Group
London,
United Kingdom
|
-$89K |
| 5 |
FFA
Founders Financial Alliance
Raleigh,
North Carolina
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $57K | – | – | – |
|
27
Citigroup
New York
| $35K | – | – | – |
|
28
Royal Bank of Canada
Toronto,
Ontario, Canada
| $26K | – | – | – |
|
|
TRSOTSOK
29
Teachers Retirement System of the State of Kentucky
Frankfort,
Kentucky
| $15K | – | – | – |
|
30
Fifth Third Bancorp
Cincinnati,
Ohio
| $11K | – | – | – |
|
31
UBS Group
Zurich,
Switzerland
| $11K | – | – | – |
|
|
TRCT
32
Tower Research Capital (TRC)
New York
| $9K | – | – | – |
|
|
SFS
33
Sowell Financial Services
North Little Rock,
Arkansas
| $6K | – | – | – |
|
34
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $5K | – | – | – |
|
35
EARNEST Partners
Atlanta,
Georgia
| $1K | – | – | – |
|
|
CS
36
Credit Suisse
Zurich,
Switzerland
| – | -$412K | – | – |
|
|
FFA
37
Founders Financial Alliance
Raleigh,
North Carolina
| – | -$2K | – | – |
|
|
GCP
38
GSA Capital Partners
London,
United Kingdom
| – | -$308K | – | – |
|
|
WG
39
Winton Group
London,
United Kingdom
| – | -$89K | – | – |
|
|
WVP
40
Worth Venture Partners
Fort Lee,
New Jersey
| – | -$210K | – | – |
|
APVO Hedge Fund Activity: Q4 2020 in Review
1 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Aptevo Therapeutics (APVO) for Q4 2020, worth a combined $107M — up 2,034% from $5M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new APVO positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $48.7M. The largest seller was Credit Suisse, cutting an estimated $412K.
- 1 institutional investor held Aptevo Therapeutics (APVO) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $107M of Aptevo Therapeutics stock for Q4 2020, up 2,034% quarter-over-quarter.
- 1 fund opened new Aptevo Therapeutics positions in Q4 2020 and 0 closed out, a net change of +1 holder.
- The largest Aptevo Therapeutics buyer in Q4 2020 was Tang Capital Management, an estimated $48.7M added.
- The largest Aptevo Therapeutics seller in Q4 2020 was Credit Suisse, an estimated $412K sold.
Based on aggregated 13F filings for Q4 2020.